Making Tomorrow’s
Cancer Treatment Better

We are Isofol

Isofol is a publicly listed biotechnology company in clinical phase that is developing the drug candidate arfolitixorin that aims to increase the efficacy of standard treatments for patients with severe forms of cancer.

Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.

Isofol’s shares are traded on Nasdaq Stockholm.

Ongoing study

Latest press releases

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

10 Apr 2026 Regulatory

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

31 Mar 2026 Regulatory

Isofol secures license rights for arfolitixorin in autism

18 Mar 2026 Regulatory

All press releases

2026-04-10

Annual report 2025

”Isofol made clear progress in 2025, focusing on resuming the clinical development of arfolitixorin. After the end of the fiscal year, we reported positive preliminary interim results from the ongoing study. Furthermore, we have had a productive dialogue with regulatory authorities, deepened our collaboration with partner Solasia Pharma K.K., and strengthened our financial position,” says CEO, Petter Segelman Lindqvist.

Pressrelease and the annual report